Enliven TherapeuticsNASDAQ: ELVN

Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (NCT05304377) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic.

The consensus price target hints at a 43% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Enliven Therapeutics reached a 52-week high following the release of promising proof of concept data from an initial trial of its blood cancer treatment. The company shared results from a Phase 1 study of its drug ELVN-001 in CML patients who have not responded well to existing treatments.

BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.

Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fund its pipeline, which includes two phase 1 candidates. ELVN-001 targets chronic myeloid leukemia and shows promise in preclinical tests, while ELVN-002 is a selective HER2 inhibitor with potential in HER2-driven cancers.